{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:15Z","timestamp":1787009595531,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim was to describe the clinical profile and outcomes in patients with antisynthetase syndrome (ASS) from a tertiary care centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical data and investigations of all patients classified as ASS by Connors criteria over 5\u2009years were recorded, and they were followed up prospectively. The median (interquartile range) was used for descriptive statistics. Clinical variables between the Jo-1 and non-Jo-1 groups and between patients with and without anti-Ro52 antibodies were compared using the \u03c72 test. Survival analysis was done using the log rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 28 patients (23 females) had a median age of 42.5 (34.8\u201352.3)\u2009years, with a disease duration of 1.75 (0.6\u20133.8)\u2009years at diagnosis, and had a follow-up of 2 (0.25\u20134.25)\u2009years. Seronegative arthritis was seen in 23 of 28 patients. Non-specific interstitial pneumonia was seen in 19 patients with interstitial lung disease (ILD). Antibodies to Jo-1 (n\u2009=\u200917) were more frequent than non-Jo-1 antibodies (n\u2009=\u200911; five anti-PL-12, four anti-PL-7 and two anti-EJ). There was no significant difference in the prevalence of myositis (P\u2009=\u20090.07) or ILD (P\u2009=\u20090.11) between groups. Anti-Ro52 antibodies were more frequently found in the non-Jo-1 group (P\u2009=\u20090.006, \u03d5\u2009=\u20090.51). A partial or complete improvement with treatment was seen in three-quarters of the patients. Five patients succumbed to the illness. Better survival was seen in the Jo-1 group (P\u2009=\u20090.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The most typical presenting manifestation of ASS in our cohort was isolated seronegative arthritis. Non-specific interstitial pneumonia was the commonest ILD pattern. Patients with antibodies to Jo-1 had better survival compared with non-Jo-1. The non-Jo-1 aminoacyl-transfer RNA synthetases had a strong association with anti-Ro52 antibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkab054","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:27:27Z","timestamp":1636108047000},"page":"ii10-ii18","source":"Crossref","is-referenced-by-count":11,"title":["Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience"],"prefix":"10.1093","volume":"5","author":[{"given":"Sreejitha Kodakkattil","family":"Sreevilasan","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6251-7828","authenticated-orcid":false,"given":"Phanikumar","family":"Devarasetti","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra Kumar","family":"Narahari","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Nizam\u2019s Institute of Medical Sciences, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitha","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Rajasekhar","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"2021110514270482400_rkab054-B1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12016-016-8528-9","article-title":"Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: a review of the literature and report of the experience of AENEAS collaborative group","volume":"52","author":"Cavagna","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021110514270482400_rkab054-B2","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti-Jo-1 positive antisynthetase syndrome: results from an international retrospective multicentre study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine"},{"key":"2021110514270482400_rkab054-B3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of the antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2021110514270482400_rkab054-B4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/2397198320902667","article-title":"Antisynthetase syndrome: a distinct disease spectrum","volume":"5","author":"Huang","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2021110514270482400_rkab054-B5","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3899\/jrheum.111604","article-title":"Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use","volume":"39","author":"Stanciu","year":"2012","journal-title":"J Rheumatol"},{"key":"2021110514270482400_rkab054-B6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"2021110514270482400_rkab054-B7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/injr.injr_40_19","article-title":"Meeting report: MyoIN \u2013 Pan-India collaborative network for myositis research","volume":"14","author":"Gupta","year":"2019","journal-title":"Indian J Rheumatol"},{"key":"2021110514270482400_rkab054-B8","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021110514270482400_rkab054-B9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"key":"2021110514270482400_rkab054-B10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021110514270482400_rkab054-B11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the antisynthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2021110514270482400_rkab054-B12","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of the antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2021110514270482400_rkab054-B13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/RHU.0000000000001779","article-title":"Anti-Jo-1 syndrome often misdiagnosed as rheumatoid arthritis (for many years): a single-center experience","volume":"27","author":"Kumar","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2021110514270482400_rkab054-B14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2021110514270482400_rkab054-B15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00296-016-3494-3","article-title":"Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis","volume":"36","author":"Srivastava","year":"2016","journal-title":"Rheumatol Int"},{"key":"2021110514270482400_rkab054-B16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0970-2113.173055","article-title":"Antisynthetase syndrome: an under-recognised cause of interstitial lung disease","volume":"33","author":"Maturu","year":"2016","journal-title":"Lung India"},{"key":"2021110514270482400_rkab054-B17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo-1-and anti-PL7\/PL12 positive patients with the antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2021110514270482400_rkab054-B18","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/keu404","article-title":"Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients","volume":"54","author":"Lefevre","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2021110514270482400_rkab054-B19","first-page":"44","article-title":"Timing of onset affects arthritis presentation pattern in antisynthetase syndrome","volume":"36","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2021110514270482400_rkab054-B20","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/art.1780331106","article-title":"A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis\/dermatomyositis","volume":"33","author":"Oddis","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2021110514270482400_rkab054-B21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/ard.2007.078907","article-title":"Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome","volume":"68","author":"Meyer","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021110514270482400_rkab054-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies. New and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021110514270482400_rkab054-B23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021110514270482400_rkab054-B24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","article-title":"Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy","volume":"109","author":"Rutjes","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"2021110514270482400_rkab054-B25","doi-asserted-by":"crossref","first-page":"415272","DOI":"10.5402\/2012\/415272","article-title":"Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma","volume":"2012","author":"Ferreira","year":"2012","journal-title":"ISRN Rheumatol"},{"key":"2021110514270482400_rkab054-B26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/14397595.2015.1091155","article-title":"Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52","volume":"26","author":"Yamasaki","year":"2016","journal-title":"Modern Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/Supplement_2\/ii10\/41090504\/rkab054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/Supplement_2\/ii10\/41090504\/rkab054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T09:54:53Z","timestamp":1673690093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/5\/Supplement_2\/ii10\/6421479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":26,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2021,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkab054","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]}}}